Clinical trial · Interventional
Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension
Effects of the TNF-alpha Inhibiton on Blood Pressure, Hemodynamic Parameters and Biomarkers in Resistant Hypertension
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Resistant hypertension (RH) is characterized by high blood pressure (BP) in spite of concurrent use of three or more antihypertensive agents of different classes, combined at optimal doses. Currently it has been largely discussed the influence of inflammation in RH. The BP variation promotes increased expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha, interleukins 1 and 6. It was showed that treatment with TNF-α inhibitor improves BP and endothelial function, and reduces arterial stiffness in patients with rheumatoid arthritis. Recently, it was demonstrated that TNF-α levels are increased in RH subjects compared to normotensives. This study aims to assess whether the acute inhibition of TNF-α changes hemodynamic parameters, such as mean BP levels in RH.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypertension | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Infliximab | Biological | — | UNRESOLVED |
| Saline | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- TNF-alpha inhibitor drug
- description
- Infliximab infusion (TNF-α inhibitor, 3 mg/kg, 250mL)
- interventionNames
- Biological: Infliximab
- type
- PLACEBO_COMPARATOR
- label
- Placebo drug
- description
- Saline infusion (250mL)
- interventionNames
- Other: Saline
Primary outcomes (1)
- measure
- Mean blood pressure in mmHg
- timeFrame
- 15 minutes
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * the diagnosis recommended by the AHA Statment on Resistant Hypertension (2008) * a 6-month period clinic follow-up * give written informed consent form Exclusion Criteria: * secondary Hypertension * pseudoresistance hypertension (poor medication adherence and white coat hypertension) * patients with symptomatic ischemic heart disease, impaired renal function, liver disease and history of stroke, myocardial infarction and peripheral vascular diseases * pregnant women * smoking * autoimmune diseases
References
Publications (0)
Data not yet available